Market Cap N/A
Revenue (ttm) 84.51M
Net Income (ttm) -60.64M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 304
Avg Vol 18,892
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 79%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-n...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 652 4500
Address:
1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States
Alex1m2
Alex1m2 Mar. 12 at 2:18 PM
$FBIOP $FBIO For those who don't know, Zell has reopend his Sub-stack and is also writing on X about the company.
1 · Reply
CabinFever208
CabinFever208 Mar. 2 at 4:06 PM
$FBIOP Thinking others may have figured this one out....such a good buy opportunity for a nice gain and some big dividends...not sexy, just a nice play on a debt instrument!
2 · Reply
IBUYSELLHOLD
IBUYSELLHOLD Feb. 26 at 11:59 PM
$FBIOP/ Nice !
0 · Reply
makrodimutross
makrodimutross Feb. 26 at 8:40 PM
$FBIOP nice to see this work its way up to 1/2 liquidation preference. Market is jockeying for reinstatement. Agree with Sawnchey, redemption is a few years out, but by then, it may be worth it to LR to simply keep the Preferreds paid in perpetuity as another source of income. I believe He does hold around 127,000 of these shares.
0 · Reply
Sawnchey
Sawnchey Feb. 26 at 9:13 AM
$FBIOP While I am prepared for anything, I am anticipating the restoration of the dividend this year. I think at this point the company is capitalised enough to bring them out of "survival mode", and in a position where a one-off payment of ~14m and then ~7m additional burn per year would be preferable than being locked out of access to equity financing. I am not predicting a redemption though, because I think the 25 dollar face value is so high that it would be an inefficient use of cash. It would be effectively advancing 10 years of dividends upfront, while holding onto the cash allows the interest to offset about half the dividend anyways and gives significantly more flexibility and safety. In terms of timeframe I think that it may happen sometime after May, as this will give greater clarity on the Emrosi launch tempo across Q4 and Q1 and give the leadership some time to consider all options on how to deploy the cash most effectively.
1 · Reply
makrodimutross
makrodimutross Feb. 25 at 9:12 PM
$FBIOP $FBIO this is the cleanest high-signal low-noise statement in recent postings, and it only has 3 likes. Common stock is pinned, and it's not because of "AI SHORT BOT ALGO"...etc. Management needs to make good to the senior securities holders first, in order to get to Joe Pantginis' 17 dollar PT.
1 · Reply
crazysnake
crazysnake Feb. 24 at 2:05 PM
$FBIOP hope they will pay you guys but i would ratter see them invest in mbio and avenue to keep that multi billion dollard pipeline alive
0 · Reply
char13
char13 Feb. 24 at 10:22 AM
$FBIOP go go go
0 · Reply
crazysnake
crazysnake Feb. 24 at 2:57 AM
$FBIOP you think management will restore prefered shares dividend or sit on a pile of cash for 2 years?
0 · Reply
aak12345
aak12345 Feb. 23 at 6:54 PM
$FBIOP $FBIO the price action wants to force management to do something about preferreds. Let's hope management responds when. Payment is received.
4 · Reply
Latest News on FBIOP
Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 10:41 PM EST - 4 months ago

Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript

FBIOP


Fortress Biotech Investigated by the Portnoy Law Firm

Oct 1, 2025, 3:45 PM EDT - 5 months ago

Fortress Biotech Investigated by the Portnoy Law Firm


Sun Pharma to Acquire Checkpoint Therapeutics

Mar 9, 2025, 10:06 PM EDT - 1 year ago

Sun Pharma to Acquire Checkpoint Therapeutics

CKPT


Alex1m2
Alex1m2 Mar. 12 at 2:18 PM
$FBIOP $FBIO For those who don't know, Zell has reopend his Sub-stack and is also writing on X about the company.
1 · Reply
CabinFever208
CabinFever208 Mar. 2 at 4:06 PM
$FBIOP Thinking others may have figured this one out....such a good buy opportunity for a nice gain and some big dividends...not sexy, just a nice play on a debt instrument!
2 · Reply
IBUYSELLHOLD
IBUYSELLHOLD Feb. 26 at 11:59 PM
$FBIOP/ Nice !
0 · Reply
makrodimutross
makrodimutross Feb. 26 at 8:40 PM
$FBIOP nice to see this work its way up to 1/2 liquidation preference. Market is jockeying for reinstatement. Agree with Sawnchey, redemption is a few years out, but by then, it may be worth it to LR to simply keep the Preferreds paid in perpetuity as another source of income. I believe He does hold around 127,000 of these shares.
0 · Reply
Sawnchey
Sawnchey Feb. 26 at 9:13 AM
$FBIOP While I am prepared for anything, I am anticipating the restoration of the dividend this year. I think at this point the company is capitalised enough to bring them out of "survival mode", and in a position where a one-off payment of ~14m and then ~7m additional burn per year would be preferable than being locked out of access to equity financing. I am not predicting a redemption though, because I think the 25 dollar face value is so high that it would be an inefficient use of cash. It would be effectively advancing 10 years of dividends upfront, while holding onto the cash allows the interest to offset about half the dividend anyways and gives significantly more flexibility and safety. In terms of timeframe I think that it may happen sometime after May, as this will give greater clarity on the Emrosi launch tempo across Q4 and Q1 and give the leadership some time to consider all options on how to deploy the cash most effectively.
1 · Reply
makrodimutross
makrodimutross Feb. 25 at 9:12 PM
$FBIOP $FBIO this is the cleanest high-signal low-noise statement in recent postings, and it only has 3 likes. Common stock is pinned, and it's not because of "AI SHORT BOT ALGO"...etc. Management needs to make good to the senior securities holders first, in order to get to Joe Pantginis' 17 dollar PT.
1 · Reply
crazysnake
crazysnake Feb. 24 at 2:05 PM
$FBIOP hope they will pay you guys but i would ratter see them invest in mbio and avenue to keep that multi billion dollard pipeline alive
0 · Reply
char13
char13 Feb. 24 at 10:22 AM
$FBIOP go go go
0 · Reply
crazysnake
crazysnake Feb. 24 at 2:57 AM
$FBIOP you think management will restore prefered shares dividend or sit on a pile of cash for 2 years?
0 · Reply
aak12345
aak12345 Feb. 23 at 6:54 PM
$FBIOP $FBIO the price action wants to force management to do something about preferreds. Let's hope management responds when. Payment is received.
4 · Reply
r_sr
r_sr Feb. 23 at 6:54 PM
$FBIOP Just the beginning of the run, based on today's news on sale of PRV - This story now is "buy and wait and be handsomely paid for waiting for 2 - 4 months" - TWO upsides - $4.00 / share dividend arrears to be paid and the re-adjustment of the stock price inn the direction of par value of $25.00 as soon as regular dividends are restored - The Risk - Reward ratio on this is so compelling
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 23 at 5:47 PM
$FBIOP RSI: 63.98, MACD: 0.1779 Vol: 0.73, MA20: 11.87, MA50: 10.86 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
dsoape
dsoape Feb. 23 at 5:01 PM
$FBIO $FBIOP i agree, great job. this company has made a huge turnaround. The next step seems obvious, restore the dividends & restore investor confidence
0 · Reply
makrodimutross
makrodimutross Feb. 23 at 4:55 PM
$FBIO $FBIOP The 100m proceeds to Fortress will completely clear out the company's debt, and leave Cyprium enough to initiate the P1 study for AAV-ATP7A (which, in combination with ZYCUBO, may effectively cure Menkes Disease). When this deal is executed, there will no longer be an issue with continuing as a going concern. Well done, management and Lindsay Rosenwald.
2 · Reply
BosFreedom
BosFreedom Feb. 23 at 4:41 PM
0 · Reply
Alex1m2
Alex1m2 Feb. 23 at 3:59 PM
$FBIOP When should we expect dividend reinstatement?
1 · Reply
Sawnchey
Sawnchey Feb. 23 at 2:44 PM
$FBIO $FBIOP Below is the segment report from the latest 10-Q published November 14th. On that day the stock price was 2.62. In the 10-Q to be published in May: the following is likely to be different: 1: The Pink Highlight is likely to be a profit, rather than a loss. 2: The Yellow Highlight will likely be somewhere in the rigion of 140 Million dollars. 3: The Green Highlight will likely have a number above 100 Million dollars. So +50% on the common stock since then doesn’t sound like the correct number!
0 · Reply
FinSUN
FinSUN Feb. 23 at 1:58 PM
$FBIOP Back to $19.
1 · Reply
FinSUN
FinSUN Feb. 23 at 1:56 PM
0 · Reply
Sawnchey
Sawnchey Feb. 23 at 1:48 PM
$FBIO $FBIOP Some quick and dirty maths: 205m minus obligations (Cyprium Preferred repurchase, NIH, repayment of Oaktree Notes), times 0.74 for fortress proportional pwnership of Cyprium, divided by roughly 33m shares (assuming equality between preferred and common). The interest per share in this PRV is a few cents shy of 4 DOLLARS. If you are able to purchase common stock below this number, then you are getting in below 1x price to book after discounting literally everything except the PRV. This company could not unreasonably be valued in the double digits, compared to the value ratios similar companies enjoy.
0 · Reply
makrodimutross
makrodimutross Feb. 20 at 6:33 PM
$FBIO Why? Perhaps the market is assuming management has implied that making good on their arrears to the holders of $FBIOP is not a priority to them at this time. Maybe the market thinks that the management thinks: "Eventually they will get paid, and they should be happy with that". If the market is convinced that this is the attitude management has towards the senior securities holders, what must it think of the attitude management may have towards the common shareholders? I believe some clarity will be delivered in the upcoming annual filing. If there is no expression of insider confidence through form 4s after the blackout period, we may be looking a groundhog afraid of its shadow. Another year of winter for the company.
2 · Reply
makrodimutross
makrodimutross Feb. 18 at 7:29 PM
$FBIOP $FBIO I've said it before and I'll say it again: Suspended dividends in FBIOP are an albatross around the neck of this company. ------------------------------------------------------ ...'God save thee, ancient Mariner! From the fiends, that plague thee thus!— Why look'st thou so?'—With my cross-bow I shot the ALBATROSS... ... ...O happy living things! no tongue Their beauty might declare: A spring of love gushed from my heart, And I blessed them unaware: Sure my kind saint took pity on me, And I blessed them unaware. The self-same moment I could pray; And from my neck so free The Albatross fell off, and sank Like lead into the sea.
2 · Reply